{"filings":[{"id":101799,"accession_number":"0001193125-26-105099","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Savara signs lease for new HQ in Yardley, PA; 5-year term starting July 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Lease for 10,795 sq ft at 19 W. College Ave, Yardley, PA; term 7/1/2026 to 12/1/2031.","Base rent starts at ~$28,337/mo, 2% annual increases; aggregate base rent ~$1.78M over term.","Security deposit $28,337; additional costs for operating expenses, taxes, utilities.","Relocation of headquarters from Langhorne, PA to Yardley, PA."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101798,"accession_number":"0001193125-26-023378","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2026-01-27T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"Savara amends Hercules loan; adds $75M drawdown tied to FDA approval of MOLBREEVI","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Amends $105M loan agreement; new $45M and $30M tranches available upon FDA approval of MOLBREEVI for aPAP.","First Post-Approval Tranche of $45M must be drawn within 120 days or by June 30, 2027.","Second $30M tranche available after first tranche drawn or expired, same deadline.","Financial covenant compliance dates extended: unrestricted cash to Apr 2027, revenue covenant to Sep 2027 if market cap low.","Lenders granted first-priority security interest in IP, converting to negative pledge if RTW Purchase Agreement terminated and $50M+ cash held."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":101797,"accession_number":"0001193125-26-008301","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Savara updates corporate presentation; no material new disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Corporate presentation posted on IR website and furnished as exhibit.","Reaffirms focus on rare respiratory diseases; no new clinical or financial data.","No changes to guidance, pipeline, or leadership disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118135,"accession_number":"0001193125-25-258629","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Savara prices $130M public offering of common stock and pre-funded warrants at $4.20/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["23.8M shares at $4.20/share and 7.1M pre-funded warrants at $4.199/warrant for gross proceeds of $130M.","Underwriters granted 30-day option to purchase up to an additional 4.6M shares.","Proceeds to fund clinical development and regulatory approval of MOLBREEVI, plus commercialization and launch prep in US and EU.","Offering expected to close October 31, 2025, subject to customary conditions.","Jefferies, Piper Sandler, and Guggenheim Securities are joint book-running managers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118134,"accession_number":"0001193125-25-256290","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2025-10-29T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Savara secures $75M royalty funding from RTW for MOLBREEVI; also discloses securities class action","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RTW commits $75M upon FDA approval of MOLBREEVI for autoimmune PAP; funds to support U.S. launch and repay debt.","Royalty rates tiered from 7.0% to 1.0% of U.S. net sales; 7.0% tier rises to 9.5% if prior-year sales fall short.","Royalty capped at $187.5M; company expects effective rate in low-single digits over life of agreement.","Securities class action filed Sept 8, 2025 alleging misstatements about MOLBREEVI regulatory filings; company intends to defend."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":134573,"accession_number":"0001193125-25-193507","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2025-09-02T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Savara updates corporate presentation; no material new disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Updated corporate presentation posted on IR website and furnished as Exhibit 99.1.","Presentation available at savarapharma.com/investors/events-presentations.","No specific financial or operational updates provided in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151437,"accession_number":"0001193125-25-137150","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2025-06-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Savara stockholders elect directors, ratify auditors, and approve say-on-pay at 2025 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected with at least 118.7 million votes in favor each.","Ratification of RSM US LLP as auditor for 2025 received 151.3 million votes for, 28,827 against.","Advisory vote on executive compensation approved with 120.6 million for (97.3%).","Stockholders selected '1 year' as preferred frequency for future say-on-pay votes (122.9 million votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":151436,"accession_number":"0001193125-25-126273","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Savara receives FDA Refusal to File for MOLBREEVI BLA; resubmission expected Q4 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA requested additional CMC data; RTF not due to safety or efficacy concerns.","Company plans Type A meeting within 30 days to align on next steps.","BLA for autoimmune PAP was submitted March 2025; resubmission targeted for Q4 2025.","Technology transfer for second-source drug substance manufacturer on track; three PPQ batches completed.","MOLBREEVI retains Fast Track, Breakthrough Therapy, and Orphan Drug status."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170316,"accession_number":"0001193125-25-067658","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2025-03-31T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Savara terminates ATM equity offering agreement with Evercore, effective April 2, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Delivered notice to Evercore on March 31, 2025 terminating the ATM Agreement under Section 12(b).","Agreement permitted sales of up to $100M in common stock; no shares sold since December 31, 2024.","Termination effective April 2, 2025; no penalties incurred by the Company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170315,"accession_number":"0001193125-25-064145","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2025-03-26T23:59:59+00:00","items":["1.01","1.02","2.03","7.01","9.01"],"status":"ready","headline":"Savara secures up to $200M non-dilutive debt from Hercules Capital, $30M drawn at close","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$30M initial draw used to repay existing $26.5M SVB debt; up to $170M additional available contingent on FDA approval of MOLBREEVI and other milestones.","Interest-only period of 36 months (extendable to 60 months upon FDA approval); floating rate of prime+1.45% (floor 6%+1.45%).","No warrants issued; loan matures April 1, 2030; collateral includes tangible assets (negative pledge on IP).","Milestone triggers: $80M available upon FDA approval (by end of 2025 if priority review), $20M upon revenue milestone post-2027, $70M at Hercules discretion."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170314,"accession_number":"0001193125-25-011453","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Savara sets 2025 executive bonus targets; CEO bonus $330k, other execs $165k-$200k","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["CEO Matthew Pauls target bonus $330,000 (50% of base salary).","CFO Dave Lowrance and COO Rob Lutz each target $188,400 (40% of base).","CMO Raymond Pratt target $200,400; CBO Anne Erickson $165,080; CCO Braden Parker $180,000.","CEO bonus based 100% on corporate goals; other execs 75% corporate, 25% individual measures.","Actual payouts subject to board discretion and performance goal achievement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":170313,"accession_number":"0001193125-25-005034","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Savara updates corporate presentation; no material new information disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Corporate presentation updated and posted on IR website on January 13, 2025.","Presentation titled 'Developing New Therapies for Rare Respiratory Diseases'.","No specific financial data or material events provided in the filing.","Presentation furnished as Exhibit 99.1 but contains no new material substantive disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220426,"accession_number":"0001193125-24-171564","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Savara prices $100M common stock offering at $3.81/sh, 26.2M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of ~$100M from 26,246,720 shares at $3.81 per share.","Offering expected to close July 1, 2024; subject to customary conditions.","Investors include Bain Capital Life Sciences, Farallon, Frazier, Wellington, Nantahala, TCGX, First Light.","Jefferies, Piper Sandler, and Guggenheim Securities are joint book-running managers.","Offered under existing effective shelf registration statement (File No. 333-279274)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220425,"accession_number":"0001193125-24-168501","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2024-06-26T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Savara reports positive Phase 3 IMPALA-2 results for molgramostim in aPAP; primary endpoint met","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: DLCO improved by 6.00% predicted at Week 24 vs placebo (p=0.0007).","Statistically significant improvement sustained at Week 48: DLCO 6.90% (p=0.0008).","SGRQ Total Score statistically significant at Week 24 (-6.59 points, p=0.0072); SGRQ Activity and exercise capacity nominally significant.","Well-tolerated; no drug-related discontinuations; 97% completed double-blind; all patients elected 96-week open-label.","Company plans to complete BLA submission to FDA in first half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220422,"accession_number":"0001193125-24-158429","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K/A","filed_at":"2024-06-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Savara stockholders approve 2024 Omnibus Incentive Plan adding 11.7M new shares","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders approved 2024 Omnibus Incentive Plan at June 6, 2024 annual meeting.","Plan reserve includes 11.7M new shares plus any shares remaining under prior plan and forfeited awards.","Plan authorizes grants of options, SARs, restricted stock, RSUs, and other awards to eligible individuals.","Key terms: exercise price at least 100% FMV, max term 10 years, Non-Employee Director annual limit $1M total value.","Outstanding prior 2015 plan awards continue; no new grants under prior plan after effective date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":220424,"accession_number":"0001193125-24-157366","cik":1160308,"company_name":"Savara Inc","ticker":"SVRA","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Savara shareholders approve officer exculpation charter amendment and 2024 omnibus incentive plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment to certificate of incorporation allowing officer exculpation under Delaware law approved (88.6M for, 14.1M against).","2024 Omnibus Incentive Plan approved with 91.3M votes for, 11.4M against.","All six director nominees elected; Matthew Pauls received 101.5M votes for.","Ratification of RSM US LLP as auditor passed with 120.4M votes for, 385K against.","Advisory vote on executive compensation approved with 98.3M votes for, 4.4M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":1072793981.4270635,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}